ARTIDIS Device for Pancreatic Cancer

(ANoPs Trial)

This trial examines a new test called NEO-Match® to determine if it can predict how well patients with suspected pancreatic cancer will respond to treatment before surgery. It will also compare this test to the standard method doctors use to check for pancreatic cancer. Participants will provide an additional biopsy sample, but their normal treatment will remain unchanged. This study targets individuals needing a biopsy of a suspicious spot in their pancreas. The goal is to gather information that could improve future diagnosis and treatment choices for pancreatic cancer. Additionally, the ARTIDIS ART-1 Device will assist in the evaluation process. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could enhance future diagnostic and treatment options for pancreatic cancer.

The trial does not require you to stop taking your current medications. You will continue to receive standard treatment and care, which is not influenced by the study.

Previous studies have tested the ARTIDIS ART-1 device for safety in examining pancreatic cancer tissue. Research shows that this device requires no additional procedures beyond a standard biopsy. It simply gathers more information from the biopsy without altering the usual care patients receive.

Although direct safety data is unavailable, the ARTIDIS ART-1 device is not an experimental treatment. It serves as a tool to help doctors better understand tumors, posing minimal risk to patients since it doesn't change their treatment. Participants in studies with similar devices have not reported any major side effects.

The ARTIDIS ART-1 device is unique because it offers a new technique for assessing pancreatic cancer that differs from traditional treatments like chemotherapy, surgery, and radiation. Instead of directly treating the cancer, this device measures the physical properties of tissue, which can provide deeper insights into how the disease behaves. Researchers are excited about this because it could lead to more personalized treatment plans by predicting how a patient's cancer might respond to different therapies. This innovative approach has the potential to improve outcomes by tailoring treatments more effectively to each individual's specific cancer characteristics.

This trial will evaluate the ARTIDIS ART-1 Device for its effectiveness in analyzing the physical properties of tumors in participants with suspected pancreatic cancer. Studies have shown that the ARTIDIS nanomechanical profiling platform, which includes the NEO-Match® test, effectively analyzes these properties. This technology identifies the nature of pancreatic cancer by measuring tissue stiffness or softness, crucial for detecting cancerous growths. Research indicates that the ARTIDIS device provides detailed insights into tumor mechanics and may predict patient responses to treatments before surgery. Initial findings suggest that using this device could improve diagnosis and treatment planning by offering more precise information than standard methods. While the device does not treat cancer, it supports better decision-making in managing the condition.¹²³⁶⁷